Total
0
Shares
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall - The Market Herald
CEO, Dr Sean Hall
Source: Medlab Clinical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Medlab Clinical (MDC) has received a notice of intention from the European Patent Office
  • The soon-to-be-granted patent will cover the use of the company’s NanoCelle sub-micron delivery platform in Europe, including the United Kingdom
  • This will be the second patent granted for Medlab’s NanoCelle delivery system, after the Australian patent was granted in September 2020
  • The company has also filed patent applications in New Zealand, Singapore, Hong Kong, the United States, and Canada
  • Medlab Clinical is up 6.25 per cent and trading at 26 cents per share

Biotech company Medlab Clinical (MDC) has received a notice of intention from the European Patent Office (EPO).

The notice indicates that the EPO intends to grant a patent covering the use of the company’s proprietary NanoCelle sub-micron delivery platform. NanoCelle creates nano-sized water-soluble particles, which allow for the optimised delivery of particles which have issues with solubility or degradation. 

The patent was filed in March 2016 under the title “Transmucosal and transdermal delivery systems”. The soon-to-be-granted patent will specifically cover use of NanoCelle in European member states, as well as the United Kingdom, until 2036.

Medlab Clinical’s CEO, Dr Sean Hall, commented that the company is delighted with the recognition represented by the upcoming patent.

“Receiving Notice of Intent from the European Patent Office represents another important validation of our NanoCelle drug delivery platform, offering NanoCelle protection in one of the world’s largest markets,” he said.

“The grant will not only bolster the competitive advantage of our pharmaceutical and nutraceutical portfolio, it will also support our robust R&D pipeline and commercial partnering focus,” he added.

This will be the second patent granted for Medlab’s NanoCelle delivery ststem. The company was granted the Australian patent for the product in September 2020.

Medlab has also filed patent applications for NanoCelle in numerous countries including New Zealand, Singapore, Hong Kong, the United States and Canada.

Medlab Clinical is up 6.25 per cent, trading at 26 cents per share at 2:59 pm AEST.

MDC by the numbers
More From The Market Herald
Jayex Healthcare (ASX:JHL) - Executive Chairman, Michael Boyd - The Market Herald

" Jayex Healthcare (ASX:JHL) to divest hospital queue management business

Jayex Healthcare (JHL) has entered into an asset sale to divest its on-premises hospital queue management business.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences’ (ASX:RHY) clinician network joins ColoSTAT trial

Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT.
Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

" Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

Shares in antiviral drug developer Island Pharmaceuticals (ILA) have jumped almost 150 per cent following the completion of a $7.5 million IPO.
Revasum (ASX:RVS) raises almost $7M via institutional entitlement offer

" Universal Biosensors (ASX:UBI) signs tech development deals

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.